Rosada Tomasz, Napiórkowska-Baran Katarzyna, Cała Łukasz, Alska Ewa, Paulina Kęsicka, Czarnowska Marta, Bartuzi Zbigniew
Department and Clinic of Allergology, Clinical Immunology and Internal Diseases, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Dr Jan Biziel University Hospital No. 2 in Bydgoszcz, Poland.
Students' Scientific Club of Clinical Immunology and Internal Diseases At, Department and Clinic of Allergology, Clinical Immunology and Internal Diseases, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Dr Jan Biziel University Hospital No. 2 in Bydgoszcz, Poland.
Public Health Pract (Oxf). 2023 Jun;5:100354. doi: 10.1016/j.puhip.2022.100354. Epub 2022 Dec 24.
The aim of this study was to determine the degree of safety and possible risk of acute allergic reactions following mRNA COVID-19 vaccination among a group of patients predisposed to allergic diseases.
The study survey took place between May 2021 and February 2022. Each participant completed an initial pre-vaccination questionnaire during patient eligibility assessment for vaccination, and two subsequent questionnaires were completed approximately 21 days after the first and second doses of vaccination.
The study included 52 patients aged >18 years. Participants were a select group of patients who, due to a history of severe allergic disease, were not eligible for vaccination at the COVID-19 Vaccination Points available in Poland.
None of the patients developed serious allergic complications in the form of anaphylaxis. There were no statistically significant differences between the first vaccination and the second vaccination in terms of symptoms, the time of onset and duration. The age of the participants did not correlate statistically with the occurrence of symptoms following the first or second vaccination.
Based on the study results, it can be concluded that mRNA COVID-19 vaccines show a favourable safety profile for patients with a history of allergic disease and constitute the optimal strategy for fighting the SARS-CoV-2 pandemic. The study results support the recommendation of COVID-19 vaccinations for people predisposed to allergic diseases due to the clear benefits of vaccination over the possible risk of adverse events.
本研究旨在确定一组易患过敏性疾病的患者接种mRNA新冠疫苗后急性过敏反应的安全程度及可能风险。
研究调查于2021年5月至2022年2月进行。每位参与者在疫苗接种资格评估期间完成一份初始的接种前问卷，在接种第一剂和第二剂疫苗后约21天完成另外两份问卷。
该研究纳入了52名年龄大于18岁的患者。参与者是一组因有严重过敏疾病史而不符合波兰现有新冠疫苗接种点接种条件的特定患者群体。
没有患者出现以过敏反应形式的严重过敏并发症。在症状、发作时间和持续时间方面，第一次接种和第二次接种之间没有统计学上的显著差异。参与者的年龄与第一次或第二次接种后症状的发生没有统计学关联。
根据研究结果，可以得出结论，mRNA新冠疫苗对有过敏疾病史的患者显示出良好的安全性，是对抗SARS-CoV-2大流行的最佳策略。研究结果支持为易患过敏性疾病的人推荐接种新冠疫苗，因为接种疫苗的明显益处超过了可能的不良事件风险。
